The 36-month beta value for AIM is at -0.31. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AIM is 56.31M, and currently, shorts hold a 0.91% of that float. The average trading volume for AIM on January 03, 2025 was 480.25K shares.
AIM) stock’s latest price update
The stock of AIM ImmunoTech Inc (AMEX: AIM) has increased by 2.86 when compared to last closing price of 0.22.Despite this, the company has seen a gain of 11.04% in its stock price over the last five trading days. globenewswire.com reported 2024-12-17 that OCALA, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated December 11, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards.
AIM’s Market Performance
AIM’s stock has risen by 11.04% in the past week, with a monthly rise of 8.30% and a quarterly drop of -7.77%. The volatility ratio for the week is 9.84% while the volatility levels for the last 30 days are 9.76% for AIM ImmunoTech Inc The simple moving average for the last 20 days is 8.10% for AIM’s stock, with a simple moving average of -32.88% for the last 200 days.
AIM Trading at -0.59% from the 50-Day Moving Average
After a stumble in the market that brought AIM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.00% of loss for the given period.
Volatility was left at 9.76%, however, over the last 30 days, the volatility rate increased by 9.84%, as shares surge +7.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.43% lower at present.
During the last 5 trading sessions, AIM rose by +10.50%, which changed the moving average for the period of 200-days by -45.16% in comparison to the 20-day moving average, which settled at $0.2064. In addition, AIM ImmunoTech Inc saw 12.73% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AIM starting from MITCHELL WILLIAM M, who sale 4,580 shares at the price of $0.19 back on Dec 19 ’24. After this action, MITCHELL WILLIAM M now owns 118,549 shares of AIM ImmunoTech Inc, valued at $884 using the latest closing price.
Equels Thomas K, the CEO & President of AIM ImmunoTech Inc, purchase 22,727 shares at $0.21 during a trade that took place back on Dec 18 ’24, which means that Equels Thomas K is holding 1,680,695 shares at $4,682 based on the most recent closing price.
Stock Fundamentals for AIM
Current profitability levels for the company are sitting at:
- -146.88 for the present operating margin
- 0.2 for the gross margin
The net margin for AIM ImmunoTech Inc stands at -125.94. The total capital return value is set at -8.0. Equity return is now at value -187.58, with -115.46 for asset returns.
Based on AIM ImmunoTech Inc (AIM), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at -7.57. The debt to equity ratio resting at 0.94. The interest coverage ratio of the stock is -25.67.
Currently, EBITDA for the company is -31.68 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 89.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.75.
Conclusion
In conclusion, AIM ImmunoTech Inc (AIM) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
